BALYASNY ASSET MANAGEMENT L.P. - 30 Sep 2025 SCHEDULE 13G Report for Avalo Therapeutics Inc. Common Stock, par value $0.001 per share (AVTX)

Filing Manager
BALYASNY ASSET MANAGEMENT L.P.
Reporting Manager
Balyasny Asset Management L.P.
Security
Avalo Therapeutics Inc. Common Stock, par value $0.001 per share
Symbol
AVTX
Shares outstanding
13,142,058 shares
Disclosed Ownership
817,436 shares
Ownership
6.2%
Form type
SCHEDULE 13G
Filing time
14 Nov 2025, 06:01:14 UTC
Date of event
30 Sep 2025
Next filing
17 Feb 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"BALYASNY ASSET MANAGEMENT L.P. disclosed 6.2% ownership in Avalo Therapeutics Inc. Common Stock, par value $0.001 per share (AVTX) on 30 Sep 2025."

Quick Takeaways

  • BALYASNY ASSET MANAGEMENT L.P. filed SCHEDULE 13G for Avalo Therapeutics Inc. Common Stock, par value $0.001 per share (AVTX).
  • Disclosed ownership: 6.2%.
  • Date of event: 30 Sep 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Nov 2025, 06:01.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (5)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Balyasny Asset Management L.P. 6.2% 817,436 817,436 0 /s/ Scott Schroeder Scott Schroeder / Authorized Signatory
BAM GP LLC 6.2% 817,436 817,436 0 /s/ Scott Schroeder Scott Schroeder / Authorized Signatory
Balyasny Asset Management Holdings LP 6.2% 817,436 817,436 0 /s/ Scott Schroeder Scott Schroeder / Authorized Signatory
Dames GP LLC 6.2% 817,436 817,436 0 /s/ Scott Schroeder Scott Schroeder / Authorized Signatory
Dmitry Balyasny 6.2% 817,436 817,436 0 /s/ Dmitry Balyasny Dmitry Balyasny / Self

Sponsored